SCIENTIFIC EVIDENCE

A tri-specific EGFR/cMet/VEGF antibody demonstrates potent multi-mechanistic activity in preclinical triple-negative breast cancer models.

The Journal of biological chemistry

Pu P, Jin Y, Zhang S, Xu Y, Chen P, Zhou F, Sun P, Jiang H, Huang S, Chen L, Fu M, Zha Z, MacWilliams MP, Chiu ML.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2026

Cancer Research

Immunology

Microbiology

No items found.

Key Finding

The findings show that TAVO412, a tri-specific antibody that recognized cMet, dual epitopes of EGFR, and vascular endothelial growth factor could elicit antitumor activity in TNBC. Overall, TAVO412 demonstrated great preclinical utility against TNBC.

Countstar Connection

Within the study, Countstar (model not specified) measured cell numbers in tumor-cell samples during sample-quality assessment.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online